Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.
“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Read moreEMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.
Read moreDual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.
Read more